Magnetic-induction hyperthermia. Results of a 5-year multi-institutional national cooperative trial in advanced cancer patients

F. K. Storm, H. W. Baker, E. F. Scanlon, H. P. Plenk, P. M. Meadows, S. C. Cohen, C. E. Olson, J. W. Thomson, J. D. Khandekar, Denise Roe

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Nine US institutions performed 14,807 Phase I-II treatments of magnetic-induction (Magnetrode [Henry Medical Electronics, Inc., Los Angeles, CA]) hyperthermia in 1170 adults. All had advanced tumors: 20% had untreated inoperable cancer or disease progression despite surgery (10%), radiation therapy (XRT) (3%), chemotherapy (27%), or combinations (40%); 67% had pain; and 79% had reduced activity. Eighteen percent were advanced primaries, 26% were recurrent, and 56% metastatic tumors in the head and neck (7%), body wall (7%), extremity (4%), abdominal cavity (17%), pelvis (17%), lung (15%), or liver (30%); 36% were <5 cm and 64% ≥5 cm. Treatments were to safe tolerance for 30 to 60 minutes for five or more treatments. Results in 960 evaluable patients were complete response 9% (1-34 months, median, 7 months), partial response 18% (1-39 months; median, 4 months), minimal response 10% (1-15 months; median, 3 months), and no change 33% (1-32 months; median, 3 months), with decreased pain in 30% and improved activity in 21%, independent of histologic type or site. Regression was dependent on treatment type and minimum temperature: heat only, 23%; heat + XRT, 60%; heat + less-than-standard XRT because of prior XRT failure, 39%, heat + intravenous (IV) chemotherapy, 28%; heat + same previously failed IV chemotherapy, 20%; heat + intraarterial (IA) chemotherapy, 28%; heat + same previously failed IA chemotherapy, 15%; heat + standard XRT + chemotherapy, 58%; heat + less-than-standard XRT + chemotherapy, 47%; <40°C, 31%; 40 to 40.9°C, 45%; 41 to 41.9°C, 54%; 42 to 42.9°C, 47%; 43 to 43.9°C, 40%; 44 to 44.9°C, 33%; 45 to 45.9°C, 55%, 46 to 46.9°C, 63%; >47°C, 100%. There were 49 (0.33%) skin burns and 2 systemic injuries (stomach ulcer at 1 month; lung fibrosis at 9 months). This trial indicates that localized hyperthermia has a significant role in palliation of human advanced solid cancer.

Original languageEnglish (US)
Pages (from-to)2677-2687
Number of pages11
JournalCancer
Volume55
Issue number11
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

Fever
Neoplasms
Medical Electronics
Lung
Los Angeles
Abdominal Cavity
Stomach Ulcer
Pelvis
Burns
Disease Progression
Fibrosis
Neck
Radiotherapy
Extremities
Head
Drug Therapy
Pain
Skin
Liver
Wounds and Injuries

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Magnetic-induction hyperthermia. Results of a 5-year multi-institutional national cooperative trial in advanced cancer patients. / Storm, F. K.; Baker, H. W.; Scanlon, E. F.; Plenk, H. P.; Meadows, P. M.; Cohen, S. C.; Olson, C. E.; Thomson, J. W.; Khandekar, J. D.; Roe, Denise.

In: Cancer, Vol. 55, No. 11, 1985, p. 2677-2687.

Research output: Contribution to journalArticle

Storm, FK, Baker, HW, Scanlon, EF, Plenk, HP, Meadows, PM, Cohen, SC, Olson, CE, Thomson, JW, Khandekar, JD & Roe, D 1985, 'Magnetic-induction hyperthermia. Results of a 5-year multi-institutional national cooperative trial in advanced cancer patients', Cancer, vol. 55, no. 11, pp. 2677-2687. https://doi.org/10.1002/1097-0142(19850601)55:11<2677::AID-CNCR2820551124>3.0.CO;2-O
Storm, F. K. ; Baker, H. W. ; Scanlon, E. F. ; Plenk, H. P. ; Meadows, P. M. ; Cohen, S. C. ; Olson, C. E. ; Thomson, J. W. ; Khandekar, J. D. ; Roe, Denise. / Magnetic-induction hyperthermia. Results of a 5-year multi-institutional national cooperative trial in advanced cancer patients. In: Cancer. 1985 ; Vol. 55, No. 11. pp. 2677-2687.
@article{06ab79933d4d444ba0335d2ca61cdf6c,
title = "Magnetic-induction hyperthermia. Results of a 5-year multi-institutional national cooperative trial in advanced cancer patients",
abstract = "Nine US institutions performed 14,807 Phase I-II treatments of magnetic-induction (Magnetrode [Henry Medical Electronics, Inc., Los Angeles, CA]) hyperthermia in 1170 adults. All had advanced tumors: 20{\%} had untreated inoperable cancer or disease progression despite surgery (10{\%}), radiation therapy (XRT) (3{\%}), chemotherapy (27{\%}), or combinations (40{\%}); 67{\%} had pain; and 79{\%} had reduced activity. Eighteen percent were advanced primaries, 26{\%} were recurrent, and 56{\%} metastatic tumors in the head and neck (7{\%}), body wall (7{\%}), extremity (4{\%}), abdominal cavity (17{\%}), pelvis (17{\%}), lung (15{\%}), or liver (30{\%}); 36{\%} were <5 cm and 64{\%} ≥5 cm. Treatments were to safe tolerance for 30 to 60 minutes for five or more treatments. Results in 960 evaluable patients were complete response 9{\%} (1-34 months, median, 7 months), partial response 18{\%} (1-39 months; median, 4 months), minimal response 10{\%} (1-15 months; median, 3 months), and no change 33{\%} (1-32 months; median, 3 months), with decreased pain in 30{\%} and improved activity in 21{\%}, independent of histologic type or site. Regression was dependent on treatment type and minimum temperature: heat only, 23{\%}; heat + XRT, 60{\%}; heat + less-than-standard XRT because of prior XRT failure, 39{\%}, heat + intravenous (IV) chemotherapy, 28{\%}; heat + same previously failed IV chemotherapy, 20{\%}; heat + intraarterial (IA) chemotherapy, 28{\%}; heat + same previously failed IA chemotherapy, 15{\%}; heat + standard XRT + chemotherapy, 58{\%}; heat + less-than-standard XRT + chemotherapy, 47{\%}; <40°C, 31{\%}; 40 to 40.9°C, 45{\%}; 41 to 41.9°C, 54{\%}; 42 to 42.9°C, 47{\%}; 43 to 43.9°C, 40{\%}; 44 to 44.9°C, 33{\%}; 45 to 45.9°C, 55{\%}, 46 to 46.9°C, 63{\%}; >47°C, 100{\%}. There were 49 (0.33{\%}) skin burns and 2 systemic injuries (stomach ulcer at 1 month; lung fibrosis at 9 months). This trial indicates that localized hyperthermia has a significant role in palliation of human advanced solid cancer.",
author = "Storm, {F. K.} and Baker, {H. W.} and Scanlon, {E. F.} and Plenk, {H. P.} and Meadows, {P. M.} and Cohen, {S. C.} and Olson, {C. E.} and Thomson, {J. W.} and Khandekar, {J. D.} and Denise Roe",
year = "1985",
doi = "10.1002/1097-0142(19850601)55:11<2677::AID-CNCR2820551124>3.0.CO;2-O",
language = "English (US)",
volume = "55",
pages = "2677--2687",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Magnetic-induction hyperthermia. Results of a 5-year multi-institutional national cooperative trial in advanced cancer patients

AU - Storm, F. K.

AU - Baker, H. W.

AU - Scanlon, E. F.

AU - Plenk, H. P.

AU - Meadows, P. M.

AU - Cohen, S. C.

AU - Olson, C. E.

AU - Thomson, J. W.

AU - Khandekar, J. D.

AU - Roe, Denise

PY - 1985

Y1 - 1985

N2 - Nine US institutions performed 14,807 Phase I-II treatments of magnetic-induction (Magnetrode [Henry Medical Electronics, Inc., Los Angeles, CA]) hyperthermia in 1170 adults. All had advanced tumors: 20% had untreated inoperable cancer or disease progression despite surgery (10%), radiation therapy (XRT) (3%), chemotherapy (27%), or combinations (40%); 67% had pain; and 79% had reduced activity. Eighteen percent were advanced primaries, 26% were recurrent, and 56% metastatic tumors in the head and neck (7%), body wall (7%), extremity (4%), abdominal cavity (17%), pelvis (17%), lung (15%), or liver (30%); 36% were <5 cm and 64% ≥5 cm. Treatments were to safe tolerance for 30 to 60 minutes for five or more treatments. Results in 960 evaluable patients were complete response 9% (1-34 months, median, 7 months), partial response 18% (1-39 months; median, 4 months), minimal response 10% (1-15 months; median, 3 months), and no change 33% (1-32 months; median, 3 months), with decreased pain in 30% and improved activity in 21%, independent of histologic type or site. Regression was dependent on treatment type and minimum temperature: heat only, 23%; heat + XRT, 60%; heat + less-than-standard XRT because of prior XRT failure, 39%, heat + intravenous (IV) chemotherapy, 28%; heat + same previously failed IV chemotherapy, 20%; heat + intraarterial (IA) chemotherapy, 28%; heat + same previously failed IA chemotherapy, 15%; heat + standard XRT + chemotherapy, 58%; heat + less-than-standard XRT + chemotherapy, 47%; <40°C, 31%; 40 to 40.9°C, 45%; 41 to 41.9°C, 54%; 42 to 42.9°C, 47%; 43 to 43.9°C, 40%; 44 to 44.9°C, 33%; 45 to 45.9°C, 55%, 46 to 46.9°C, 63%; >47°C, 100%. There were 49 (0.33%) skin burns and 2 systemic injuries (stomach ulcer at 1 month; lung fibrosis at 9 months). This trial indicates that localized hyperthermia has a significant role in palliation of human advanced solid cancer.

AB - Nine US institutions performed 14,807 Phase I-II treatments of magnetic-induction (Magnetrode [Henry Medical Electronics, Inc., Los Angeles, CA]) hyperthermia in 1170 adults. All had advanced tumors: 20% had untreated inoperable cancer or disease progression despite surgery (10%), radiation therapy (XRT) (3%), chemotherapy (27%), or combinations (40%); 67% had pain; and 79% had reduced activity. Eighteen percent were advanced primaries, 26% were recurrent, and 56% metastatic tumors in the head and neck (7%), body wall (7%), extremity (4%), abdominal cavity (17%), pelvis (17%), lung (15%), or liver (30%); 36% were <5 cm and 64% ≥5 cm. Treatments were to safe tolerance for 30 to 60 minutes for five or more treatments. Results in 960 evaluable patients were complete response 9% (1-34 months, median, 7 months), partial response 18% (1-39 months; median, 4 months), minimal response 10% (1-15 months; median, 3 months), and no change 33% (1-32 months; median, 3 months), with decreased pain in 30% and improved activity in 21%, independent of histologic type or site. Regression was dependent on treatment type and minimum temperature: heat only, 23%; heat + XRT, 60%; heat + less-than-standard XRT because of prior XRT failure, 39%, heat + intravenous (IV) chemotherapy, 28%; heat + same previously failed IV chemotherapy, 20%; heat + intraarterial (IA) chemotherapy, 28%; heat + same previously failed IA chemotherapy, 15%; heat + standard XRT + chemotherapy, 58%; heat + less-than-standard XRT + chemotherapy, 47%; <40°C, 31%; 40 to 40.9°C, 45%; 41 to 41.9°C, 54%; 42 to 42.9°C, 47%; 43 to 43.9°C, 40%; 44 to 44.9°C, 33%; 45 to 45.9°C, 55%, 46 to 46.9°C, 63%; >47°C, 100%. There were 49 (0.33%) skin burns and 2 systemic injuries (stomach ulcer at 1 month; lung fibrosis at 9 months). This trial indicates that localized hyperthermia has a significant role in palliation of human advanced solid cancer.

UR - http://www.scopus.com/inward/record.url?scp=0021918522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021918522&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19850601)55:11<2677::AID-CNCR2820551124>3.0.CO;2-O

DO - 10.1002/1097-0142(19850601)55:11<2677::AID-CNCR2820551124>3.0.CO;2-O

M3 - Article

VL - 55

SP - 2677

EP - 2687

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -